Yahoo Finance • 2 months ago
The Medical Genome Initiative presents a paper in an effort to expand patient access to sequencing Originally published on Illumina News Center NORTHAMPTON, MA / ACCESSWIRE / April 17, 2024 / A recent literature review, published in the... Full story
Yahoo Finance • 3 months ago
In this article, we will discuss the 14 Best Medical Device Stocks To Buy Now. You can skip our detailed analysis of the Medical Device Industry and go directly to the 5 Best Medical Device Stocks To Buy Now. The healthcare sector relies... Full story
Yahoo Finance • 3 months ago
In this article, we're going to take a look at 10 biggest stocks targeted by activist investors right now. You can skip ahead and take a look at more stocks that made our list by jumping straight to the top 5 biggest stocks targeted by act... Full story
Yahoo Finance • 4 months ago
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The Russell 100... Full story
Yahoo Finance • 4 months ago
On February 22, 2024, Jacob Thaysen, CEO of Illumina Inc (NASDAQ:ILMN), made a significant insider purchase, acquiring 7,330 shares of the company's stock, as reported in a recent SEC Filing. This transaction has caught the attention of ma... Full story
Yahoo Finance • 4 months ago
In this article, we discuss the 15 Best Shareholder Activism Law Firms. If you would like to discuss our detailed discussion and analysis of the shareholder activism space as of 2024, you can skip it and go directly to 5 Best Shareholder A... Full story
Yahoo Finance • 4 months ago
Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments... Full story
Yahoo Finance • 5 months ago
Ensemble Capital Management, an investment management company, released its fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund saw exceptionally excellent absolute and relative performance in the fourt... Full story
Yahoo Finance • 6 months ago
SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 Presentati... Full story
Yahoo Finance • 6 months ago
Grail’s screening test, called Galleri, could one day help save countless lives by catching cancer in the bloodstream early. After losing in court [against the Federal Trade Commission](https://www.wsj.com/health/healthcare/court-sides-wit... Full story
Yahoo Finance • 6 months ago
Dec 18 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Gene-sequencing company Illumina said on Sunday it will divest itself of canc... Full story
Yahoo Finance • 6 months ago
Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws, Continue reading... Full story
Yahoo Finance • 6 months ago
(Adds background in paragraphs 4, 8-9, 12) Dec 17 (Reuters) - Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and European antitrust enforcers for mor... Full story
Yahoo Finance • 6 months ago
(Reuters) -Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and European antitrust enforcers for more than two years and faced fierce opposition from ac... Full story
Yahoo Finance • 6 months ago
SAN DIEGO, Dec. 17, 2023 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL. The divestiture will be executed through a third-party sale or capital markets transaction, consistent with the Eu... Full story
Yahoo Finance • 6 months ago
A federal appeals court said the U.S. government was right to challenge Illumina purchase of cancer-test developer Grail, but still sent the case back to the Federal Trade Commission for reconsideration. A three-judge panel found the deal... Full story
Yahoo Finance • 6 months ago
By Diane Bartz and Mike Scarcella (Reuters) - A U.S. appeals court on Friday struck down the U.S. Federal Trade Commission’s order against Illumina's purchase of cancer diagnostic test maker Grail, a former subsidiary, saying the agency h... Full story
Yahoo Finance • 6 months ago
(Updates with details from ruling, case background in paragraphs 2-12) By Diane Bartz and Mike Scarcella Dec 15 (Reuters) - A U.S. appeals court on Friday struck down the U.S. Federal Trade Commission’s order against Illumina's purchase... Full story
Yahoo Finance • 6 months ago
Illumina (ILMN) seeks to resolve it's battle with EU regulators regarding acquisition of biotech company Grail. Earlier this year, Illumina received a $476 million fine from EU authorities over the deal. It comes as Pfizer (PFE) says it ha... Full story
Yahoo Finance • 6 months ago
(Recasts, adds court adviser to give non-binding opinion on March 21 in paragraph 10) By Foo Yun Chee LUXEMBOURG, Dec 12 (Reuters) - Illumina on Tuesday accused EU antitrust regulators of over-extending their powers in their scrutiny of... Full story
Home
Money Search
Trending Sports
Gallery
Shop
Blog
Examples
Data & Glossary
Elements of Bball
Harden Maze
About
